Abstract-Diseases are caused by the deregulation of cellular networks, leading to faulty physiological functions. Different diseases can have common deregulated molecular pathways, particularly if they partially share phenotypes. These commonalities are frequently represented as an overlap of disease-related cellular subnetworks. The discovery of the overlaps and thus genes simultaneously associated with multiple diseases can shed light on the molecular pathomechanisms and provide new polyvalent therapeutic targets.
I. INTRODUCTION
Cellular function is the result of complex interactions between its components. The recent development of highthroughput experimental methodologies and bioinformatic techniques, made available more knowledge and information at different biological levels, namely molecular interaction data [1] . Networks provide a convenient graphical representation of molecular interactions thanks to its generality, simplicity and ability to detect complex patterns [2] . There are various types of interaction networks, including protein-protein interaction (PPI), metabolic, signalling and transcription-regulatory networks that in turn interact between them, resulting in the coherent behaviour of the cell. The cell's constituents are represented as nodes connected to each other by links representing the interactions between the two components, forming a network or graph. The links can be undirected, indicating an association or physical interaction between proteins, or directed, representing a cause-effect relationship, like regulatory interactions between transcription factors (DNA-binding proteins) and a target gene to modulate its expression, or signalling interactions that represent information flow. Diseases can be modeled as network perturbations (such as mutations, deletions, copy number variations or expression changes) that spread from diseasecausative genes to other interacting elements, affecting their function, making it possible to predict new disease-associated genes and biological pathways at a much lower cost compared to the conventionally used genome-wide techniques [2, 3] .
Since the elements of cellular networks are highly interconnected, it is expected that biological processes will share certain pathways at some point. Considering pathological mechanisms as disturbed processes, we can represent them as disease modules and in similarly, it is expected that when two diseases share phenotypic characteristics, their modules will be prone to overlap [4] . Network-based approaches can therefore be developed to predict the overlap between molecularly linked diseases and aid the development of novel polyvalent therapeutic options, or even reveal approved drugs that can be used to treat several linked diseases.
This work is the extension of a network-based disease gene prioritization method proposed by Garcia-Vaquero et al. [5] , called S2B (double specific-betweenness), that aims to predict proteins in undirected PPI networks simultaneously associated with two phenotypically similar diseases. The objective of this work was to expand the S2B method to be able to analyze other cellular networks with directed links, such as signaling and gene regulatory interaction networks, and consequentially further increase the predictive potential and provide more information about the role of cellular regulatory pathways in the overlap between two related diseases.
II. STATE OF THE ART
Currently the most frequently employed approaches to identify genes involved in complex disorders are genomewide techniques, such as linkage analysis and genome-wide association studies, that can identify the chromosomal region in which unknown disease-associated genes are located, however the regions can contain up to 300 candidate genes [6] , making the experimental validation time consuming and expensive. Therefore, several computational approaches were developed to aid the prediction of novel disease-associated genes (DGs) candidates and prioritization of the most promising ones for experimental follow-up studies. When using interaction data, in particular protein interactions, it is possible to evoke the network medicine principle that claims that genes related to the same or similar disease phenotype tend to be located in a specific neighborhood of PPI networks, which means that if a few DGs are known, other genes found in their network-based vicinity most likely share the same biological functions and are associated with the same disease [7] [4] . The majority of the network-based algorithms rank candidate genes based on their distance to the known DGs, using either local network information, that ignores potential effects from distant nodes, or global network information, that analyses the whole network topology including long-range interactions [8] [9] .
Despite the increasing evidence of disease modules interconnectivity, very few network-based methods aim to predict DGs simultaneously associated with related diseases. Two approaches were recently proposed [10] [11]. Silberberg et al. [10] proposes a GLobal Approach for DIsease AssociaTed mOdule Reconstruction (GLADIATOR) for prediction of disease modules of multiple diseases simultaneously, and Akram and Liao [11] proposes a similar method, but it is applied to only one disease pair. The aim is to predict missing common genes between two diseases known to have high comorbidity but unexpectedly have a high module separation, indicating missing shared genes. The two proposed methods, however, predict new shared genes indirectly through the reconstruction of the disease modules' overlap that is maximized for the whole set of known DGs, disregarding pathways within the disease modules that can lead to different presentations of the disease and possibly losing relevant information about the common molecular pathways. Both methods are also susceptible to select new genes only because they are central in the PPI network structure and therefore will mediate the connection between several modules, but do not have a specific connection to both diseases' genes.
A. S2B method: Specific betweenness method for crossdisease network analysis
With a solution to these shortcomings, a method was proposed by Garcia-Vaquero et al. [5] called S2B (double specific-betweenness). It aims to directly predict and prioritize disease genes simultaneously associated with two related diseases, by using a variant of betweenness centrality, a measure of the frequency with which shortest paths between any pair of nodes pass through a node. The S2B approach prioritizes genes by scoring higher those that appear more frequently in shortest paths specifically linking DGs of both disease modules in PPI networks. These are more central relatively to both disease modules and are more likely to belong to the overlap. The method further guarantees that the candidate genes are specifically linked to both diseases, eliminating candidates with high specific betweenness due to their central position in the network, by computing two specificity scores that evaluate the specificity of the candidates to the DGs used and to the pathways they appear in linking both disease modules.
The performance of the S2B method was tested with artificial disease modules, which provide a well-controlled test scenario. The method is tested by intersecting two artificial disease modules and using the method to predict the overlap that is already known. The results with the artificial modules showed that the probability of being in the overlap decays as S2B scores get lower, meaning that the S2B method correctly spots the network location of the overlap.
The method was further applied to two neurodegenerative diseases, ALS and SMA, disorders with a different pathoetiology and clinical presentation, but with an evident common motor neuron degeneration phenotype and already identified common molecular pathomechanisms [12] . The results returned some new candidate proteins yet not represented in sets of known DGs, involved in several biological processes relevant for motor neuron degeneration, such as apoptosis, DNA repair, RNA processing, protein transport and cytoskeleton organization.
The results of the study suggest that the S2B method is a successful gene prediction method for disease pairs, that takes advantage of diseases with similar phenotype to uncover common molecular mechanisms. The method was, however, developed to use only undirected networks, and therefore it can be improved through the expansion to directed networks, integrating more information about the diseases and amplifying its prediction potential.
III. DIRECTED S2B METHOD
In directed networks a path connecting node A to node B it's not the same path connecting B to A, since the direction of the interactions must be coherent. To search for paths connecting two different disease modules in regulatory networks it is necessary to take into consideration the direction and its biological meaning. The directed method takes as input a directed network and seeds corresponding to known DGs from each disease, and uses a new measure of specific betweenness, that accounts with the directionality of the regulatory interactions, to prioritize candidate genes. The regulatory network used in this work integrates data from two sources: different types of regulatory interactions retrieved from OmniPath [13] and transcriptional-regulatory interactions compiled in a study of Li and Altman [14] .
A. S2B method expansion
To expand the method the R functions that implemented the undirected S2B were modified to search separately for shortest paths linking DGs in different directions going through the candidate nodes: paths going from one DG to another through the linker in only one coherent direction (S2B version 1), shortest paths going from both DGs to a linker or candidate node (S2B version 2) and paths going out of the linker to both DGs (S2B version 3). Theoretically, if we are searching for candidates in common that explain the phenotypical similarity between two diseases, then paths going from the seeds to a candidate node (used in S2B version 2) explain better how different genetic perturbations result in a common phenotypic expression. However, other types of links cannot be discarded as there may exist common disease genes that can regulate simultaneously other genes in both disease modules. The functions that implement the directed method are publicly available at https://github.com/GamaPintoLab/S2B_directed.
B. Construction of directed artificial disease modules
The method's performance testing and optimization was achieved using artificial disease modules. These modules are built around randomly chosen multiple causing nodes, around which the disease perturbation spreads according to interactions directions to phenotypical nodes (up to a maximum of two interaction distance from causal nodes). Nodes that directly regulated either causal or phenotypical nodes were also part of the disease module and were considered modifier nodes.
C. Directed S2B method performance testing
Beyond testing the S2B method's performance, when using the multiple cause artificial modules with modifiers it is also possible to test if each version detects preferentially any of the node types with higher S2B scores. Figure 1 shows the directed S2B versions performance in predicting the overlap of 2500 pairs of artificial modules and additionally a comparison between the fraction of each node type in each rank position with the total mean fraction of each node type in the overlap. The comparison can reveal if in each rank a certain type of node is overrepresented relatively to the proportion of the node types in the module. The method's performance results show that nodes with higher S2B version 1 and 3 scores have a high probability of being in the overlap, meaning that the S2B method correctly spots the network location of the overlap, and a worst performance for version 2. The node type graphs give however more information about the high ranked candidates. Modifiers of phenotypic nodes and causal nodes have an almost constant frequency in each rank, since almost all nodes in the modules can be classified as the first, and almost all causal nodes are not going to be selected as candidates. On the other hand, phenotypic nodes are clearly over-represented in higher ranked version 2 candidates, while modifiers of causal nodes are over-represented in higher ranked version 3 candidates. Since the prediction is highly dependent on the disease module structure, we recommend the use of the three versions to retrieve the most complete compendium of candidates. If the user intends to explore a particular type of candidates, we suggest the use of version 2 or 3 of the S2B method since they retrieve more specific predictions.
IV. APPLICATION TO A REAL CASE STUDY OF MOTOR NEURON DISEASES
The new directed versions of the S2B method were applied to two motor neuron diseases, Amyotrophic Lateral Sclerosis and Spinal Muscular Atrophy, studied previously with the undirected version of the method, to test the method's behavior in predicting DGs and analyze the information that can be retrieved using a signaling and gene regulatory network comparatively to the original method's results. Recent studies have discovered genetic and molecular links between ALS and SMA associated with regulatory pathways for RNA metabolism and DNA transcription and repair [12] , proving this disease-pair to be also adequate to test the directed version of the S2B method.
A. Application of the directed S2B method to ALS and SMA
The same regulatory network referred in section III was used as input to the method, within which the specific betweenness count was computed. Input DGs were identified from DisGeNet [15] [16] . Each S2B version gave a separate score to all network nodes. Before the selection of the candidates a specificity filter was applied through two scores, counting how many times a node has equal or higher specific betweenness count in the directed network when compared with randomized networks. This allows the detection of nonspecific nodes with high S2B count only due to their centrality in the network. Nodes with high S2B count and high specificity scores were then selected as candidates to DGs associated with both diseases.
B. S2B candidates' functional analysis
In order to functionally validate the predicted S2B candidates a comparative Functional Enrichment Analysis (FEA) was performed. A Gene Ontology (GO) FEA is a method to identify gene biological functions, represented as "GO terms" that are statistically over-represented in a set of genes or proteins. To demonstrate the relevance of the directed S2B method's results to both neurodegenerative diseases, the enriched GO terms in the S2B candidates were compared with the enriched GO terms in the ALS and SMA DGs, already known to be associated with mechanisms of neurodegeneration. The set of all the S2B candidates recovered proximately 60% of the DGs GO terms (significant overlap p < 0.001, randomization test performed with 1000 random sets of proteins), and each version candidates recovered approximately 26%, 47%, 43% for version 1, 2, and 3 respectively (Figure 2) . These results indicate the method extracted new functional information from the regulatory network that is not currently associated with motor neuron diseases.
An additional analysis of the specific biological functions represented by the retrieved GO terms did not reveal substantially different functional information between the directed S2B versions, but showed that collectively more transcription, signaling and apoptosis information is retrieved in comparison with the undirected S2B. Overall the method was able to predict novel candidates associated with signaling and regulatory processes known to be associated with motor neuron degeneration. Despite the successful predictions it is still necessary to further analyze the information retrieved by each S2B version and test the method with more case-studies, potentially with diseases with different degree of relatedness.
V. CONCLUSION
In this work the previously developed S2B method to prioritize proteins simultaneously associated with two diseases was extended in order to be used with signaling and regulatory networks with directed interactions, amplifying the method's predictive potential. The results of the performance tests using several types of artificial modules of different complexities revealed the directed version ability to distinguish candidates in the overlap with different roles in the disease modules. The application to the same case-study with two motor neuron diseases ALS and SMA, further demonstrated the directed method potential to retrieve new functional information compared to the undirected method, specifically useful to analyze diseases with known dysregulated regulatory mechanisms. Additionally, gene regulatory networks provide more information about the relationship between genes than gene co-expression networks, by specifying the type and direction of the regulatory dependency.
With the successful application of S2B to undirected and directed cellular networks the next step will be to integrate several networks, such as regulatory, protein-protein interactions, proteomic or metabolic networks, to capture the full range of interplay between different molecular elements. The combination of molecular interaction data specific to the disease states and specific to the affected tissues can further improve the S2B prediction accuracy.
